Sweden · Delayed Price · Currency is SEK Cereno Scientific AB Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing its lead HDAC inhibitor into a global phase IIb trial for pulmonary arterial hypertension, targeting disease modification and remission. With strong clinical progress, regulatory support, and a multi-billion dollar market opportunity, strategic partnerships and platform expansion are key priorities this year.
Fiscal Year 2025
-
Epigenetic drug programs for rare cardiovascular and lung diseases are advancing, with two Phase 2 trials set to start next year. FDA Fast Track status, global partnerships, and strong investor growth support ongoing development and potential pharma deals.
-
CS1 demonstrated safety and promising efficacy in a phase 2A PAH trial, with improvements in risk scores, heart function, and quality of life. Ongoing studies and imaging aim to confirm disease-modifying effects, with a phase 2B trial and further regulatory discussions planned.
Fiscal Year 2024
-
Focused on rare cardiovascular and pulmonary diseases, the company reported strong phase II-A results for its lead PAH program, secured FDA expanded access, and expects key regulatory milestones and long-term data in H1 next year. Operations are funded into 2026.
-
The company is advancing a rare disease-focused portfolio with CS1 showing strong safety and efficacy signals in PH, CS014 targeting IPF with a novel HDAC inhibitor, and CS585 progressing toward clinical trials for rare thrombosis. Strategic collaborations, innovative imaging, and orphan drug incentives support rapid development and commercial potential.
-
A phase IIa trial of CS1 in pulmonary arterial hypertension met safety and tolerability endpoints, with promising efficacy signals: 43% improved REVEAL Risk Score, 33% improved functional class, and 67% had sustained mPAP reduction. Preclinical and clinical data support CS1's potential to reverse disease pathology, and regulatory engagement for a pivotal trial is underway.